Gerard Espinosa
Overview
Explore the profile of Gerard Espinosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
290
Citations
3195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salman-Monte T, Cuadrado M, Galindo M, Espinosa G, Morales E, Pego-Reigosa J, et al.
Expert Opin Biol Ther
. 2025 Mar;
PMID: 40077897
Introduction: Belimumab (BEL), an anti B-lymphocyte stimulator monoclonal antibody, is the only approved biological therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Areas Covered: This review discusses BEL's...
2.
Beca S, Borrell M, Cervera R, Figueras F, Nadal A, Espinosa G, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004829
Women with adverse pregnancy outcomes suggestive of obstetric antiphospholipid syndrome (OAPS), but not fulfilling clinical and/or laboratory international classification criteria, are increasingly recognized both in clinical practice and in the...
3.
Araujo O, Espinosa G, Hernandez-Rodriguez J, Hernandez-Negrin H, Adan A, Pelegrin L, et al.
Lupus
. 2025 Jan;
34(3):243-252.
PMID: 39871549
BackgroundHydroxychloroquine is recommended for all patients with systemic lupus erythematosus (SLE) because of its efficacy and safety. Previous studies of antimalarial toxicity under non-experimental conditions have often grouped hydroxychloroquine and...
4.
Alamo J, Mont-de Torres L, Castano-Diez S, Mensa-Vilaro A, Monica Lopez-Guerra M, Zugasti I, et al.
Br J Haematol
. 2025 Jan;
206(2):565-575.
PMID: 39806534
VEXAS syndrome is a haemato-inflammatory disease caused by somatic UBA1 mutations and characterized by cytoplasmic vacuoles in myeloid and erythroid precursor cells. Although there is currently no standard treatment algorithm...
5.
Beca S, Banos N, Borrell M, Ruiz-Ortiz E, Perez-Isidro A, Cervera R, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768785
: The clinical and laboratory features of patients with non-criteria obstetric antiphospholipid syndrome (NC-OAPS), as well as their pregnancy outcomes and ideal treatment are not clearly determined. The aim of...
6.
Sota J, Ragab G, AlMaglouth I, Lopalco G, Tufan A, Direskeneli H, et al.
Joint Bone Spine
. 2024 Nov;
92(2):105819.
PMID: 39549971
Objectives: Gender impact on phenotypical expression of Behçet's disease (BD) has been specifically investigated only in a few large-scale studies. The main goal of the study was to examine gender...
7.
Rodriguez-Pinto I, Espinosa G, Cervera R
Med Clin (Barc)
. 2024 Aug;
163 Suppl 1:S31-S35.
PMID: 39174151
The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). It was first described in 1992 in...
8.
Villanueva I, Civico J, Lledo G, Matas A, Aldecoa I, Milisenda J, et al.
Clin Exp Rheumatol
. 2024 Jul;
42(8):1704-1705.
PMID: 39058478
No abstract available.
9.
Casares-Marfil D, Martinez-Bueno M, Borghi M, Pons-Estel G, Reales G, Zuo Y, et al.
Arthritis Rheumatol
. 2024 Jul;
76(11):1623-1634.
PMID: 38973605
Objective: Primary antiphospholipid syndrome (PAPS) is a rare autoimmune disease characterized by the presence of antiphospholipid antibodies and the occurrence of thrombotic events and pregnancy complications. Our study aimed to...
10.
Pinal-Fernandez I, Munoz-Braceras S, Casal-Dominguez M, Pak K, Torres-Ruiz J, Musai J, et al.
Ann Rheum Dis
. 2024 Jun;
83(11):1549-1560.
PMID: 38902010
Objectives: Autoantibodies targeting intracellular proteins are common in various autoimmune diseases. In the context of myositis, the pathologic significance of these autoantibodies has been questioned due to the assumption that...